Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Everolimus in DIPG and HGG
NCT03355794Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribociclib and everolimus in diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG) (4 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Number of adverse events at 6 months, Maximum tolerated dose and/or recommended phase 2 dose at 28 days and 1 more. Started Nov 2017; status: completed.
02
Drugs
ribociclibeverolimus
03
Conditions
diffuse intrinsic pontine glioma (DIPG)high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03355794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355794.